SCHEMBL23199735

SCHEMBL23199735

CC12CN(C(=O)O)CC1(C)CN(c1ccc(Br)cc1)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.42
HDAC4 P56524 1/20 0.41
MMP2 P08253 1/20 0.39
MMP13 P45452 1/20 0.39
ADAMTS5 Q9UNA0 1/20 0.39
MAPT P10636 6/20 0.38
ALDH1A1 P00352 4/20 0.38
CYP2C19 P33261 2/20 0.38
MAPK1 P28482 2/20 0.38
USP2 O75604 4/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP3A4 P08684 3/20 0.35
HSD17B10 Q99714 3/20 0.35
CYP1A2 P05177 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 2/20 0.34
POLB P06746 1/20 0.34
TSHR P16473 1/20 0.34
CCR1 P32246 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25389958 0.84 CA12 (0.44) AKR1C3MAPTALDH1A1MAPK1USP2
SCHEMBL22015094 0.80 RORC (0.49) MAPTALDH1A1CYP2C19USP2KMT2A
SCHEMBL23701463 0.80 RORC (0.49) MAPTALDH1A1CYP2C19USP2KMT2A
SCHEMBL23701437 0.79 KDM4E (0.55) ALDH1A1CYP2C19MAPK1USP2KMT2A
SCHEMBL23701434 0.79 KDM4E (0.41) HDAC4ALDH1A1CYP2C19MAPK1USP2
SCHEMBL25389263 0.77 KCNA5 (0.44)
SCHEMBL23701474 0.77 MAPT (0.50) MAPTALDH1A1CYP2C19USP2KMT2A
SCHEMBL22804696 0.76 CYP2C19 (0.57) ALDH1A1CYP2C19MAPK1USP2CYP3A4
SCHEMBL5015647 0.74 AKR1C3 (0.65) AKR1C3MAPTALDH1A1CYP2C19USP2
SCHEMBL27010083 0.73 AKR1C3 (0.39) AKR1C3HDAC4MMP2MMP13ADAMTS5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113365984-B LOX inhibitors 癌症研究协会皇家癌症医院 2024-10-15 CN disclosed
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-08-05 US disclosed
EP-3802541-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS The Institute of Cancer Research: Royal Cancer Hospital (GB) 2021-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS LOX, LOXL1, LOXL3 AKR1C3 398/4885HDAC4 3054/4885MMP2 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.